vedolizumab,erdafitinib
janssen,takeda
[' vedo', 'ibd', 'erda', 'vedo', 'crohn', 'vedolizumab']
vedolizumab reduces recurrence of post-op crohn s disease
- commenced at 4 weeks post op
- 8 weekly
- decreased endoscopic scores at 6/12
- safe
#geertd haens #ecco23 
Mum. Gastroenterology consultant. Interests IBD, nutrition & GI consequences of cancer treatment. Runner. Glaswegian in Manchester.